Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-Dotatate (Lutathera) (LU) in neuroendocrine tumors (NETs)

被引：0
|
作者：
Navarro Martin, M. [1 ]
Teran Brage, E. [1 ]
Campana-Diaz, E. [2 ]
Garcia-Talavera, P. [2 ]
Reguera Puertas, P. [1 ]
Rama-Alonso, S. [2 ]
Garijo-Martinez, M. C. [1 ]
Felix, L. C. [1 ]
Diaz Sanchez, P. [1 ]
Vidal Tocino, R. [1 ]
Fonseca Sanchez, E. [1 ]
机构：
[1] Univ Hosp Salamanca, Dept Med Oncol, Salamanca, Spain
[2] Univ Hosp Salamanca, Dept Nucl Med, Salamanca, Spain
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.227
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
219P
引用
收藏
页码：S95 / S95
页数：1
相关论文
共 50 条
  • [31] Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
    Parghane, Rahul V.
    Talole, Sanjay
    Prabhash, Kumar
    Basu, Sandip
    [J]. CLINICAL NUCLEAR MEDICINE, 2017, 42 (06) : 428 - 435
  • [32] Evaluation of Kidney Dose in Neuroendocrine Tumors Patients after Peptide Receptor Radionuclide Therapy using 177Lu-DOTATATE
    Hidayati, N. R.
    Poon, A.
    Willowson, K.
    Eslick, E.
    Ryu, H.
    Bailey, D. L.
    [J]. ATOM INDONESIA, 2019, 45 (03) : 147 - 152
  • [33] Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study
    Zidan, Lamiaa
    Iravani, Amir
    Oleinikov, Kira
    Ben-Haim, Simona
    Gross, David J.
    Meirovitz, Amichay
    Maimon, Ophra
    Akhurst, Tim
    Michael, Michael
    Hicks, Rodney J.
    Grozinsky-Glasberg, Simona
    Kong, Grace
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (02) : 218 - 225
  • [34] Peptide Receptor Radionuclide Therapy by 177Lu-DOTATATE of a Secreting Cervical Paraganglioma
    Deville, Agathe
    Pinigina, Iuliia
    Al Mansour, Laure
    Abeillon, Juliette
    Tordo, Jeremie
    [J]. CLINICAL NUCLEAR MEDICINE, 2022, 47 (01) : E71 - E73
  • [35] Data collection procedures for bone marrow dosimetry in peptide receptor radionuclide therapy with 177Lu-DOTATATE on neuroendocrine tumors
    Frederiksen, M. H. B.
    Klausen, T. L.
    de Nijs, R.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S631 - S631
  • [36] Radiation safety assessment of 177Lu-DOTATATE Intra-Arterial peptide receptor therapy (PRRT)
    Chauhan, M.
    Jha, A. K.
    Mithun, S.
    Parab, R.
    Nautiyal, A.
    Rangarajan, V.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S385 - S386
  • [37] Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
    Yeokyeong Shin
    Bo Hyun Moon
    Baek-Yeol Ryoo
    Heung-Moon Chang
    Kyu-pyo Kim
    Yong Sang Hong
    Tae Won Kim
    Jin-Sook Ryu
    Yong-il Kim
    Changhoon Yoo
    [J]. Targeted Oncology, 2024, 19 : 41 - 49
  • [38] In Vivo Instability of 177Lu-DOTATATE During Peptide Receptor Radionuclide Therapy
    Lubberink, Mark
    Wilking, Helena
    Ost, Amalia
    Ilan, Ezgi
    Sandstrom, Mattias
    Andersson, Camilla
    Fross-Baron, Katarzyna
    Velikyan, Irina
    Sundin, Anders
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (09) : 1337 - 1340
  • [39] Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
    Shin, Yeokyeong
    Moon, Bo Hyun
    Ryoo, Baek-Yeol
    Chang, Heung-Moon
    Kim, Kyu-pyo
    Hong, Yong Sang
    Kim, Tae Won
    Ryu, Jin-Sook
    Kim, Yong-il
    Yoo, Changhoon
    [J]. TARGETED ONCOLOGY, 2024, 19 (01) : 41 - 49
  • [40] 177Lu-Dotatate for Midgut Neuroendocrine Tumors
    Matuchansky, Claude
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14): : 1391 - 1391
12345